According to the STEP 1 trial published in the New England Journal of Medicine, patients taking semaglutide 2.4 mg (Wegovy) achieved approximately: 3% to 5% body weight loss by week 12 10% to 12% body weight loss by week 28 15% to 17% body weight loss by week 68 (maximum effect) These figures represent average outcomes in clinical trials
GLP-1 receptor agonists work by mimicking the hormone GLP-1 to regulate blood sugar and insulin levels and were initially developed as a treatment for type 2 diabetes
In addition, a high-fat diet can significantly increase the level of caspase-3 and decrease the level of bcl-2, which increases the susceptibility of cells to apoptosis and causes a series of obesity-related complications [242, 243]
GLP-1 potentiates post prandial insulin release when glucose levels rise after meals and reduce the gastric emptying time
GhatiADamPTasdemirDKatiASellamiHSezginGCet alExogenous pulmonary surfactant: a review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added clinical marker
Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER